RU2077883C1 - Композиция для внутривенного введения для защиты почек от токсического действия нефротоксичных цитостатических средств и иммуносупрессоров - Google Patents
Композиция для внутривенного введения для защиты почек от токсического действия нефротоксичных цитостатических средств и иммуносупрессоров Download PDFInfo
- Publication number
- RU2077883C1 RU2077883C1 SU894830956A SU4830956A RU2077883C1 RU 2077883 C1 RU2077883 C1 RU 2077883C1 SU 894830956 A SU894830956 A SU 894830956A SU 4830956 A SU4830956 A SU 4830956A RU 2077883 C1 RU2077883 C1 RU 2077883C1
- Authority
- RU
- Russia
- Prior art keywords
- amino acids
- nephrotoxic
- composition
- mixture
- solution
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 210000003734 kidney Anatomy 0.000 title claims abstract description 12
- 231100000331 toxic Toxicity 0.000 title claims abstract description 10
- 230000002588 toxic effect Effects 0.000 title claims abstract description 10
- 239000000824 cytostatic agent Substances 0.000 title claims abstract description 8
- 230000003589 nefrotoxic effect Effects 0.000 title claims description 11
- 231100000381 nephrotoxic Toxicity 0.000 title claims description 8
- 238000001990 intravenous administration Methods 0.000 title claims description 4
- 230000001085 cytostatic effect Effects 0.000 title abstract description 5
- 150000008575 L-amino acids Chemical class 0.000 claims abstract description 16
- 239000003018 immunosuppressive agent Substances 0.000 claims abstract description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 15
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 13
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 13
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 12
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 7
- 230000007935 neutral effect Effects 0.000 claims description 7
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 6
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 6
- 229930182844 L-isoleucine Natural products 0.000 claims description 6
- 239000004395 L-leucine Substances 0.000 claims description 6
- 235000019454 L-leucine Nutrition 0.000 claims description 6
- 229930182821 L-proline Natural products 0.000 claims description 6
- 239000004473 Threonine Substances 0.000 claims description 6
- 229960003767 alanine Drugs 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- 229960003136 leucine Drugs 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 229960002429 proline Drugs 0.000 claims description 6
- 229960001153 serine Drugs 0.000 claims description 6
- 229960002898 threonine Drugs 0.000 claims description 6
- 229960004295 valine Drugs 0.000 claims description 6
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 3
- WTWSHHITWMVLBX-DKWTVANSSA-M sodium;(2s)-2-aminobutanedioate;hydron Chemical compound [Na+].[O-]C(=O)[C@@H](N)CC(O)=O WTWSHHITWMVLBX-DKWTVANSSA-M 0.000 claims 1
- 229940124589 immunosuppressive drug Drugs 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000002512 chemotherapy Methods 0.000 description 9
- 229960004316 cisplatin Drugs 0.000 description 9
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 230000004900 autophagic degradation Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000001607 nephroprotective effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 229960005261 aspartic acid Drugs 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 230000009103 reabsorption Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010029155 Nephropathy toxic Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 230000007694 nephrotoxicity Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 210000005234 proximal tubule cell Anatomy 0.000 description 2
- 230000004202 respiratory function Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- IYVFNTXFRYQLRP-VVSTWUKXSA-N 2-[3,4-bis(2-hydroxyethoxy)phenyl]-5-hydroxy-7-(2-hydroxyethoxy)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-4h-chromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(OCCO)C=C3OC=2C=2C=C(OCCO)C(OCCO)=CC=2)=O)O1 IYVFNTXFRYQLRP-VVSTWUKXSA-N 0.000 description 1
- -1 ALA Chemical compound 0.000 description 1
- 108010055851 Acetylglucosaminidase Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 102100030122 Protein O-GlcNAcase Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004937 luminal membrane Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001095 no nephrotoxicity Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000013878 renal filtration Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3843241A DE3843241A1 (de) | 1988-12-22 | 1988-12-22 | Nephroprotektive infusionsloesung |
| DEP3843241.2 | 1988-12-22 | ||
| PCT/DE1989/000780 WO1990006769A1 (de) | 1988-12-22 | 1989-12-21 | Nephroprotektive infusionslösung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2077883C1 true RU2077883C1 (ru) | 1997-04-27 |
Family
ID=6369857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU894830956A RU2077883C1 (ru) | 1988-12-22 | 1989-12-21 | Композиция для внутривенного введения для защиты почек от токсического действия нефротоксичных цитостатических средств и иммуносупрессоров |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0408691B1 (enExample) |
| JP (1) | JPH078790B2 (enExample) |
| AT (1) | ATE110570T1 (enExample) |
| AU (1) | AU4807990A (enExample) |
| DE (2) | DE3843241A1 (enExample) |
| ES (1) | ES2063332T3 (enExample) |
| RU (1) | RU2077883C1 (enExample) |
| WO (1) | WO1990006769A1 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2191020C2 (ru) * | 1997-10-09 | 2002-10-20 | Бейкер Нортон Фармасьютикалз, Инк. | Способ предотвращения нефротоксичности, вызванной циклоспорином и такролимусом |
| RU2219925C2 (ru) * | 1996-07-30 | 2003-12-27 | Новартис Нутрицион Аг | Аминокислотные композиции и их применение при иммунодепрессии |
| RU2394580C2 (ru) * | 1999-02-23 | 2010-07-20 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Способы лечения митохондриальных нарушений |
| WO2014089526A1 (en) * | 2012-12-06 | 2014-06-12 | Bio Health Solutions, Llc | Treatment for chronic kidney disease |
| US9669010B2 (en) | 2012-12-06 | 2017-06-06 | Bio Health Solutions, Llc | Treatment for chronic kidney disease |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6224776B1 (en) | 1996-05-24 | 2001-05-01 | Cultor Corporation | Method for fractionating a solution |
| FI20010977A7 (fi) | 2001-05-09 | 2002-11-10 | Danisco Sweeteners Oy | Kromatografinen erotusmenetelmä |
| PL206018B1 (pl) | 2001-10-19 | 2010-06-30 | Isotechnika Inc | Preparat farmaceutyczny, sposób jego wytwarzania, mikroemulsja i zastosowanie tego preparatu farmaceutycznego |
| JPWO2005094813A1 (ja) * | 2004-03-31 | 2008-02-14 | 味の素株式会社 | 腎疾患用薬剤 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3414491A1 (de) * | 1984-04-17 | 1985-10-24 | Hans Dr. 8202 Bad Aibling Dietl | L-aminosaeurengemische fuer die parenterale und orale anwendung bei nierenerkrankungen |
-
1988
- 1988-12-22 DE DE3843241A patent/DE3843241A1/de active Granted
-
1989
- 1989-12-21 RU SU894830956A patent/RU2077883C1/ru active
- 1989-12-21 EP EP90900071A patent/EP0408691B1/de not_active Expired - Lifetime
- 1989-12-21 ES ES90900071T patent/ES2063332T3/es not_active Expired - Lifetime
- 1989-12-21 WO PCT/DE1989/000780 patent/WO1990006769A1/de not_active Ceased
- 1989-12-21 JP JP2500961A patent/JPH078790B2/ja not_active Expired - Lifetime
- 1989-12-21 DE DE58908288T patent/DE58908288D1/de not_active Expired - Fee Related
- 1989-12-21 AU AU48079/90A patent/AU4807990A/en not_active Abandoned
- 1989-12-21 AT AT90900071T patent/ATE110570T1/de not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| C.Skrezek, H.Bertermann, F.-P.Schulz und B.Konig, NAG - Ein sensitiver Marker fur Nierenfunktionsstorungen, Vrologe [A], 1990, 29, p.27 - 31. * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2219925C2 (ru) * | 1996-07-30 | 2003-12-27 | Новартис Нутрицион Аг | Аминокислотные композиции и их применение при иммунодепрессии |
| RU2191020C2 (ru) * | 1997-10-09 | 2002-10-20 | Бейкер Нортон Фармасьютикалз, Инк. | Способ предотвращения нефротоксичности, вызванной циклоспорином и такролимусом |
| RU2394580C2 (ru) * | 1999-02-23 | 2010-07-20 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Способы лечения митохондриальных нарушений |
| WO2014089526A1 (en) * | 2012-12-06 | 2014-06-12 | Bio Health Solutions, Llc | Treatment for chronic kidney disease |
| US9669010B2 (en) | 2012-12-06 | 2017-06-06 | Bio Health Solutions, Llc | Treatment for chronic kidney disease |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03502805A (ja) | 1991-06-27 |
| ES2063332T3 (es) | 1995-01-01 |
| AU4807990A (en) | 1990-07-10 |
| EP0408691B1 (de) | 1994-08-31 |
| ATE110570T1 (de) | 1994-09-15 |
| DE3843241C2 (enExample) | 1990-11-22 |
| EP0408691A1 (de) | 1991-01-23 |
| WO1990006769A1 (de) | 1990-06-28 |
| JPH078790B2 (ja) | 1995-02-01 |
| DE58908288D1 (de) | 1994-10-06 |
| DE3843241A1 (de) | 1990-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Clemens et al. | Dopamine depletion protects striatal neurons from ischemia-induced cell death | |
| US5523316A (en) | Intraocular irrigating solution containing agent for controlling IOP | |
| KR0145289B1 (ko) | 히스티딘 완충 복막 투석 용액 | |
| CA2147123C (en) | Use of a cell membrane permeant calcium buffer for reducing injury of mammalian cells in vivo | |
| RU2077883C1 (ru) | Композиция для внутривенного введения для защиты почек от токсического действия нефротоксичных цитостатических средств и иммуносупрессоров | |
| WO2001002004A1 (en) | Peritoneal dialysis solution containing antioxidant for treating renal failure | |
| Yatzidis | A new stable bicarbonate dialysis solution for peritoneal dialysis: preliminary report | |
| JPS5921614A (ja) | 緑内障治療用組成物 | |
| JPH05345021A (ja) | 腹膜炎によって生ずる傷害および生理学的副作用を最小にするために使用し得る腹膜透析液 | |
| LT3119B (en) | Pharmaceutical composition and process for the preparation thereof | |
| Parkins et al. | Gelatin as a plasma substitute: with particular reference to experimental hemorrhage and burn shock | |
| CN116390723B (zh) | 用于将生物素递送至线粒体的方法和组合物 | |
| Boros et al. | Oxygen free radical-induced histamine release during intestinal ischemia and reperfusion | |
| US5290538A (en) | Nephro protective infusion solutions | |
| WO1995016435A2 (en) | Improved intraocular irrigating solution containing non-steroidal antiinflammatory agent | |
| JPH10505322A (ja) | カゼインから得られるプペチドを浸透圧剤としておよび重炭酸塩イオンを緩衝剤として含む透析液 | |
| CA2035836A1 (en) | Reduction of oxyradical damage in biomedical applications | |
| RU2006224C1 (ru) | Мембраностабилизирующее и антиоксидантное лекарственное средство "рикавит" | |
| RU2285525C2 (ru) | Лекарственное средство, содержащее эффектор метаболизма глутатиона вместе с альфа-липоевой кислотой, для терапии при пересадке почек | |
| WO1994001086A1 (en) | Tissue irrigating solutions | |
| GB2037161A (en) | Preparations containing amino acids | |
| JP3824716B2 (ja) | 中心静脈投与用輸液 | |
| KINOSHITA et al. | Cyanate effects on the lens in vitro | |
| RU2276978C2 (ru) | Раствор для инъекций | |
| AU1745592A (en) | Pharmaceutical composition comprising purpurogallin useful as an antioxidant and cytoprotective agent |